Dietary Supplement Products was the largest of VitaNova Life Sciences Corp’s 4 reported lines in fiscal 2026, at $1.95M — 50% of $3.93M.
| Timing of Transfer of Good or Service | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Dietary Supplement Products | — | — | $2.65M | $1.95M |
| Sales Of Dietary Supplement | — | — | $2.65M | $1.95M |
| Sale Of Healthcare Products | — | $544.59K | — | — |
| Sales Of Healthcare Products | — | $544.59K | — | — |
| Consultancy Service Fee Income | $38.00K | $26.10K | — | — |
| Consulting Service Income | $38.00K | $26.10K | $10.84K | $15.00K |
| Other | — | — | $10.84K | $15.00K |
| Total | $76.00K | $1.14M | $5.32M | $3.93M |
In fiscal 2026, which ended April 30, 2026, the 4 revenue lines VitaNova Life Sciences Corp reported in this breakdown added up to $3.93M. That was down 26.3% from $5.32M in fiscal 2025. Dietary Supplement Products was the largest revenue line, at $1.95M or 49.6% of the total, followed by Sales Of Dietary Supplement ($1.95M, 49.6%) and Consulting Service Income ($15.00K, 0.4%). Together, the two largest revenue lines made up 99.2% of this total.
Compared with fiscal 2025, every sizeable revenue line reported in both years shrank. Dietary Supplement Products held up best, down 26.5% to $1.95M, while Sales Of Dietary Supplement fell the most, down 26.5% to $1.95M.
Dietary Supplement Products (fiscal 2025), Sales Of Dietary Supplement (fiscal 2025) and Other (fiscal 2025) were first reported as separate revenue lines during this period. The table also keeps 3 revenue lines that VitaNova Life Sciences Corp no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2023 to 2026, as reported in VitaNova Life Sciences Corp's annual filings.
Dietary Supplement was the largest of VitaNova Life Sciences Corp’s 2 reported lines in fiscal 2026, at $1.95M — 99% of $1.96M.
| Segment | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Dietary Supplement | — | — | $2.65M | $1.95M |
| Healthcare | — | $544.59K | — | — |
| Consulting Service | $38.00K | $26.10K | $10.84K | — |
| Other | — | — | — | $15.00K |
| Total | $38.00K | $570.69K | $2.66M | $1.96M |
In fiscal 2026, which ended April 30, 2026, the 2 segments VitaNova Life Sciences Corp reported in this breakdown added up to $1.96M. That is less than the $3.93M in its breakdown by revenue line, so these segments do not account for all of its revenue that year. Dietary Supplement was the largest segment, at $1.95M or 99.2% of the total, followed by Other ($15.00K, 0.8%).
Dietary Supplement (fiscal 2025) and Other (fiscal 2026) were first reported as separate segments during this period. The table also keeps 2 segments that VitaNova Life Sciences Corp no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2023 to 2026, as reported in VitaNova Life Sciences Corp's annual filings.
Transferred At Point In Time was the largest of VitaNova Life Sciences Corp’s 2 reported lines in fiscal 2026, at $1.95M — 99% of $1.96M.
| Timing Of Transfer Of Good Or Service | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Transferred At Point In Time | — | $544.59K | $2.65M | $1.95M |
| Transferred Over Time | $38.00K | $26.10K | $10.84K | $15.00K |
| Total | $38.00K | $570.69K | $2.66M | $1.96M |
In fiscal 2026, which ended April 30, 2026, the 2 revenue lines VitaNova Life Sciences Corp reported in this breakdown added up to $1.96M. That is less than the $3.93M in its breakdown by revenue line, so these revenue lines do not account for all of its revenue that year. Transferred At Point In Time was the largest revenue line, at $1.95M or 99.2% of the total, followed by Transferred Over Time ($15.00K, 0.8%).
Transferred At Point In Time was first reported as a separate revenue line in fiscal 2024. This breakdown covers every fiscal year from 2023 to 2026, as reported in VitaNova Life Sciences Corp's annual filings.
VitaNova Life Sciences Corp (VNOV) breaks its revenue down by revenue line and segment. In fiscal 2026, its largest revenue line was Dietary Supplement Products, with $1.95M or 49.6% of the total, followed by Sales Of Dietary Supplement at $1.95M (49.6%).
Dietary Supplement Products was VitaNova Life Sciences Corp's largest revenue line in fiscal 2026, with $1.95M in revenue, 49.6% of the $3.93M reported across its 4 revenue lines.
Dietary Supplement was VitaNova Life Sciences Corp's largest segment in fiscal 2026, with $1.95M in revenue, 99.2% of the $1.96M reported across its 2 segments.
Every figure is taken from VitaNova Life Sciences Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2023 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.